



Epichem Awarded Contract Extension from DNDi

15 December 2021 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company, is pleased to announce that its wholly owned subsidiary, Epichem Pty Ltd, has been awarded an extension to its current contract with Drugs for Neglected Diseases initiative (DNDi) (www.dndi.org).

The contract renewal will see Epichem continue to provide its synthetic and medicinal chemistry expertise to support DNDi's drug discovery projects, aimed at developing new treatments for neglected diseases, until 31st December 2022. The extension is expected to generate up to AUD\$1.02M in revenues for Epichem during CY 2022.

Epichem's CEO, Mr Colin La Galia said "We are delighted that the contract with DNDi has been renewed for another year and excited by what we can achieve together in partnership and collaboration to deliver the expected outcomes with our dedicated team of chemists. This will mark our 14th consecutive year with DNDi supporting their important work and we look forward to continuing our long-standing and important relationship with them."

PharmAust's Chairman Dr Roger Aston said "It is fantastic that Epichem have secured a further extension to this work with such a leading R&D organisation as DNDi".

This announcement is authorised by the Board.

Enquiries:

Mr Colin La Galia
CEO Epichem
Tel: 08 6167 5200
colin.lagaliam@epichem.com.au

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

About Epichem:

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in over 40 countries worldwide for over 18 years. Epichem has newly constructed purpose-built, state-of-the-art laboratories and has world class equipment and expertise in synthetic and medicinal chemistry to support drug discovery projects, and for the cost-effective synthesis of drug analogue libraries and intermediates. It also has a rapidly growing catalogue of pharmaceutical reference standards. Epichem also specialises in Custom Synthesis, Analytical Chemistry and Materials Science. Epichem is the winner of the WA Industry Export Award 2021 for International Health, an award also won in 2019, 2018 and 2017, the 2020 Inspiring Story of Celebrating Remarkable Resilience Nomination for WA for the Australian Export and Investment Awards and the 2021 and 2020 GHP Biotechnology Award winner for Most Innovative Chemistry Service Provider – Australia and Best in Organic Chemistry Solutions. For more information, visit www.epichem.com.au

About DNDi

DNDi is a not-for-profit product development partnership working to research and develop new treatments for neglected diseases, in particular human sleeping sickness, leishmaniasis, Chagas disease, malaria, paediatric HIV, hepatitis C, mycetoma and river blindness. DNDi was established in 2003 by the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia, Pasteur Institute, and Médecins sans Frontières (MSF). WHO/TDR acts as a permanent observer. Since 2003, the Drugs for Neglected Diseases initiative has developed 8 treatments for 5 deadly diseases, saving millions of lives. For more information visit, www.dndi.org.

About PharmAust (PAA):

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company that generated \$2.2 million in revenue in FY 2021.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.